https://doi.org/10.4081/reumatismo.2013.691

Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids

Vol. 65 No. 6 (2013)
Submitted: 8 August 2013
Accepted: 31 December 2013
Published: 17 March 2014
Systemic sclerosis, Raynaud’s phenomenon, Endothelin receptor antagonist, Bosentan, Raynaud’s condition score.
Abstract Views: 2415
PDF: 1135
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

S. Parisi
simone.parisi@hotmail.it
Struttura Complessa di Reumatologia, A.O. Città della Salute e della Scienza di Torino, Italy.
M. Bruzzone
Struttura Complessa di Reumatologia, A.O. Città della Salute e della Scienza di Torino, Italy.
C. Centanaro Di Vittorio
Struttura Complessa di Reumatologia, A.O. Città della Salute e della Scienza di Torino, Italy.
A. Laganà
Struttura Complessa di Reumatologia, A.O. Città della Salute e della Scienza di Torino, Italy.
C.L. Peroni
Struttura Complessa di Reumatologia, A.O. Città della Salute e della Scienza di Torino, Italy.
E. Fusaro
Struttura Complessa di Reumatologia, A.O. Città della Salute e della Scienza di Torino, Italy.
The objective of this study was to evaluate the efficacy of the endothelin receptor antagonist, bosentan, in patients with Raynaud’s phenomenon secondary to systemic sclerosis never treated with prostanoids and without digital ulcers. The study design is a preliminary, prospective open label trial. The patients recruited took one 62.5 mg dose of bosentan twice daily for 4 weeks, followed by 125 mg twice daily for 24 weeks. Of the 10 patients recruited, all completed the study. The reduction in Raynaud’s phenomenon attacks at week 24 from the baseline was statistically significant (Δ-1.3, P=0.0126). The Raynaud’s condition score showed a statistically significant improvement (Δ-1.4, P=0.0279), as did the visual analog pain scale (Δ-1.5, P=0.0016) at the 24th week. Bosentan appears to be effective and may be a valid alternative for the treatment of severe secondary Raynaud’s phenomenon for patients where prostanoids therapy is contraindicated or refused.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
S. Parisi, Struttura Complessa di Reumatologia, A.O. Città della Salute e della Scienza di Torino
Struttura Complessa di Reumatologia

How to Cite

Parisi, S., Bruzzone, M., Centanaro Di Vittorio, C., Laganà, A., Peroni, C., & Fusaro, E. (2014). Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids. Reumatismo, 65(6), 286–291. https://doi.org/10.4081/reumatismo.2013.691

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.